Candida dubliniensis candidemia in Australia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2003
   Trial
2. Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen.PloS one · 2012
   Article
3. Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy.Antimicrobial agents and chemotherapy · 2009
   Article
4. Molecular epidemiology of Candida albicans and its closely related yeasts Candida dubliniensis and Candida africana.Journal of clinical microbiology · 2009
   Article
5. Multilocus sequence typing reveals that the population structure of Candida dubliniensis is significantly less divergent than that of Candida albicans.Journal of clinical microbiology · 2008
   Article
6. Candida dubliniensis meningitis as delayed sequela of treated C. dubliniensis fungemia.Emerging infectious diseases · 2008
   Article
7. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.Journal of clinical microbiology · 2004
   Review
8. Candida dubliniensis infection, Singapore.Emerging infectious diseases · 2002
   Article
9. Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo.Journal of clinical microbiology · 2002
   Article
10. Serological differentiation of experimentally induced Candida dubliniensis and Candida albicans infections.Journal of clinical microbiology · 2001
    Article

Corrections and comments

• Commented on by
  Candida dubliniensis infection, Singapore.2002
• Comment on
  Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation.
• Comment on
  Candida dubliniensis fungemia: the first four cases in North America.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as